Vincerx Pharma, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Vip236 demonstrated positive signs of clinical activity, including tumor reduction, and an improved safety profile in heavily pretreated patients with metastatic solid tumors

Vip236, first-in-class small molecule-drug conjugate (smdc), preliminary phase 1 data and update on pipeline progress will be presented by management at a virtual investor event on april 8 at 2:00 pm pt

Management to host virtual investor event on april 8 to highlight preliminary phase 1 data for vip236, our first-in-class small molecule-drug conjugate (smdc) management to host virtual investor event on april 8 to highlight preliminary phase 1 data for vip236, our first-in-class small molecule-drug conjugate (smdc)

Investigators from the national institutes of health (nih) report 2 partial responses (pr) in 3 peripheral t-cell lymphoma (ptcl) patients and 1 pr in 2 double-hit diffuse large b-cell lymphoma (dh-dlbcl) patients in ongoing dose-escalation trial of enitociclib in combination with venetoclax and prednisone

Poster on vip943, a novel cd123-targeted antibody-drug conjugate (adc) from our versaptx™ platform, showcases selectivity, activity, and safety of vip943

Though early-stage results on Vincerx's (VINC) experimental drug did show signs of anti-tumor activity, the share price drops as some analysts stated that the results were below expectations.

Vincerx Pharma (NASDAQ: VINC ) stock is falling hard on Tuesday after releasing preliminary data from a Phase 1 clinical trial. Vincerx Pharma's cancer treatments did so potential in preliminary study results.

Management to host virtual investor event on April 8 to highlight preliminary Phase 1 Data for VIP236, our first-in-class small molecule-drug conjugate (SMDC) Management to host virtual investor event on April 8 to highlight preliminary Phase 1 Data for VIP236, our first-in-class small molecule-drug conjugate (SMDC)

VIP943 poster supports selectivity and safety of lead CD123 ADC, VIP943, currently in Phase 1 VIP924 poster shows this novel CXCR5-ADC compares favorably with other ADCs in clinical development Enitociclib poster expands potential clinical indications PALO ALTO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC)(“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that it will present three posters related to VIP943 (NCT06034275), VIP924 (in preclinical studies), and enitociclib (in collaboration with University of Calgary) at the 65th American Society for Hematology Meeting (ASH), taking place in San Diego California from December 9 to 12, 2023.

PALO ALTO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that Vincerx's CEO Ahmed Hamdy, M.D. and the Management Team will participate in a panel presentation and one-on-one investor meetings at the Cantor Fitzgerald Global Healthcare Conference 2023, to be held in New York, NY, September 26-28, 2023.

Vincerx Pharma shares moved higher after the biopharmaceutical company announced it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration to commence a clinical trial of its investigational therapeutic VIP943 for patients with acute myeloid leukemia and myelodysplastic syndrome.

Chardan analyst Matthew Barcus lowered the price target on Vincerx Pharma Inc (NASDAQ: VINC) to $4 from $11 and kept a Buy rating on the shares.  The company announced a strategic update to focus on its Phase Ib development of lead program VIP152 in double-hit diffuse.

PALO ALTO, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that Vincerx's management team will participate in a fireside chat and one-on-one investor meetings at the SVB Leerink 11th Annual Global Healthcare Conference, to be held virtually February 14-18, 2022.

Strengthened financial position extends expected cash runway into 2023 Strengthened financial position extends expected cash runway into 2023

First patient dosed in Phase 1b study of VIP152 in MYC-driven relapsed or refractory aggressive lymphomas and advanced solid tumors